Viatris Inc (LTS:0A5V)

$ 11.7525 0 (0%) Market Cap: 15.62 Bil Enterprise Value: 29.60 Bil PE Ratio: 0 PB Ratio: 0.79 GF Score: 69/100

Q3 2024 Viatris Inc Earnings Call Transcript
Nov 07, 2024

$11.75

Earnings
Q2 2024 Viatris Inc Earnings Call Transcript
Aug 08, 2024

$12.17 (+5.96%)

Earnings
Q4 2023 Viatris Inc Earnings Call Transcript
Feb 28, 2024

$12.64 (-6.02%)

Earnings
Viatris Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Viatris Inc at Jefferies London Healthcare Conference Transcript
Nov 15, 2023
Q3 2023 Viatris Inc Earnings Call Transcript
Nov 07, 2023

$9.11 (-1.20%)

Earnings
Q2 2023 Viatris Inc Earnings Call Transcript
Aug 07, 2023

$11.29 (+7.98%)

Earnings
Viatris Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Q1 2023 Viatris Inc Earnings Call Transcript
May 08, 2023

$9.13

Earnings
Q4 2022 Viatris Inc Earnings Call and Investor Event Transcript
Feb 27, 2023

$11.61 (+1.21%)

Earnings
Viatris Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 Viatris Inc Earnings Call Transcript
Nov 07, 2022

$11.08 (+13.36%)

Earnings
Viatris Inc at Bank of America Merrill Lynch Global Healthcare Conference Transcript
Sep 15, 2022
Q2 2022 Viatris Inc Earnings Call Transcript
Aug 08, 2022

$10.53 (+11.18%)

Earnings
Viatris Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 14, 2022
Q1 2022 Viatris Inc Earnings Call Transcript
May 09, 2022

$10.39 (+6.13%)

Earnings
Viatris Inc at Barclays Global Healthcare Conference Transcript
Mar 16, 2022
Viatris Inc at Raymond James Institutional Investors Conference Transcript
Mar 08, 2022
Q4 2021 Viatris Inc Earnings Call Transcript
Feb 28, 2022

$11.37 (-19.92%)

Earnings
Viatris Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Dec 01, 2021
Q3 2021 Viatris Inc Earnings Call Transcript
Nov 08, 2021

$14.64 (+7.13%)

Earnings
Viatris Inc at Bank of America Global Healthcare Conference (Virtual) Transcript
Sep 15, 2021
Viatris Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 10, 2021
Q2 2021 Viatris Inc Earnings Call Transcript
Aug 09, 2021

$14.44 (+3.88%)

Earnings
Viatris Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Viatris Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 18, 2021
Viatris Inc at BofA Securities 2021 Health Care Conference Transcript
May 11, 2021
Q1 2021 Viatris Inc Earnings Call Transcript
May 10, 2021

$15.23 (+8.56%)

Earnings
Viatris Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 10, 2021
Viatris Inc Investor Day Transcript
Mar 01, 2021
Viatris Inc 2021 Financial Guidance Call Transcript
Feb 22, 2021
Viatris Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021

Viatris Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 18, 2021 / 01:10PM GMT

Release Date Price: $16.16 (+1.76%)

Transcript

Daniel James Busby

RBC Capital Markets, Research Division - Assistant VP

I'm Dan Busby, the pharmaceuticals analyst at RBC Capital Markets. Our next company presenting this morning is Viatris, which was created not too long ago by the combination of Mylan and Pfizer's former Upjohn business.

I'm joined this morning by Viatris' Chief Executive Officer, Michael Goettler; as well as the company's Chief Financial Officer, Sanjeev Narula.

Michael, before we jump into Q&A, why don't I turn it over to you for a minute or 2 just to provide some brief background on Viatris and the rationale for last year's deal for those investors who may not be as familiar with the story.

Michael Goettler

Viatris Inc. - CEO & Executive Director

Sure. Dan, thank you very much, and thanks for having us today. And I would say this conference really comes at a great time for us. As you know, as you just said, Viatris as a combined company, is still a relatively new company, formed a little bit less than 6 months ago, in November. And the vision we had was to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.